Market capitalization | $457.57m |
Enterprise Value | $60.74m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.78 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-196.92m |
Free Cash Flow (TTM) Free Cash Flow | $-145.30m |
Cash position | $398.98m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
11 Analysts have issued a Cullinan Oncology Inc forecast:
11 Analysts have issued a Cullinan Oncology Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.31 -0.31 |
0%
0%
|
|
EBITDA | -197 -197 |
3%
3%
|
EBIT (Operating Income) EBIT | -197 -197 |
3%
3%
|
Net Profit | -167 -167 |
9%
9%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on 15 September, 2016 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Nadim Ahmed |
Employees | 111 |
Founded | 2016 |
Website | cullinantherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.